Report in English with a Dutch summary (KCE reports 45A)

218 Screening for Colorectal Cancer KCE reports vol.45
11 REFERENCES
1. Wilson J, Jungner F. Principles and practice of screening for disease. Public Health
Papers, No 34. 1968;Geneva WHO.
2. de Visser M, van Ballegooijen M, Bloemers SM, van Deventer SJH, Jansen JBMJ,
Jespersen J, et al. Report on the Dutch consensus development meeting for
implementation and further development of population screening for colorectal
cancer based on FOBT. Cellular Oncology. 2005;27(1):17-29.
3. Nederlandse gezondheidsraad. Advies Wet bevolkingsonderzoek: verschillende
vormen van screening op darmkanker.
http://www.healthcouncil.nl/pdf.php?ID=1215&p=1#search=%22COCAST%20advies
%20%22. 2005.
4. Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis
on The Netherlands program. Acta Cytol. 2002;46(4):619-29.
5. Nationale Raad voor de Volksgezondheid. Juridisch-ethisch referentiekader
preventie. Zoetermeer. 1994;publication no. 6-94.
6. Klabunde CN, Vernon SW, Nadel MR, Breen N, Seeff LC, Brown ML. Barriers to
colorectal cancer screening: A comparison of reports from primary care physicians
and average-risk adults. Medical Care. 2005;43(9):939-44.
7. Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in
cancer screening. J Natl Cancer Inst. 2000;92(16):1280-2.
8. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al.
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate
cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981-90.
9. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet.
2002;359(9309):881-4.
10. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J
Natl Cancer Inst. 2002;94(13):958-60.
11. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked
increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst.
2005;97(2):142-6.
12. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended
lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl
Cancer Inst. 2006;98(11):748-56.
13. Patz EF, Jr. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo
Lung Project. J Natl Cancer Inst. 2006;98(11):724-5.
14. Mambourg F, Van den Bruel A, Devriese S, Leys M, Vinck I, Lona M, et al. Health
Technology Assessment: prostate-specific-antigen (PSA) voor
prostaatkankerscreening. Belgian Federal Healthcare Knowledge Center. 2006;KCE
Reports vol. 31A.
15. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of
cancer screening. J Natl Cancer Inst. 2002;94(3):167-73.
16. Mapp TJ, Hardcastle JD, Moss SM, Robinson MH. Survival of patients with colorectal
cancer diagnosed in a randomized controlled trial of faecal occult blood screening.
Br J Surg. 1999;86(10):1286-91.
17. Kaplan RM. Screening for cancer: are resources being used wisely? Recent results in
cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le
cancer. 2005;166(-):315-34.
18. Moayyedi P, Achkar E. Does fecal occult blood testing really reduce mortality? A
reanalysis of systematic review data. Am J Gastroenterol. 2006;101(2):380-4.
19. Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of
outcomes research. Journal of the National Cancer Institute. Monographs. 2004:45-
55.